4//SEC Filing
Garfield Alastair 4
Accession 0001104659-25-015318
CIK 0001649904other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 9:44 PM ET
Size
14.5 KB
Accession
0001104659-25-015318
Insider Transaction Report
Form 4
Garfield Alastair
Chief Scientific Officer
Transactions
- Award
Restricted Stock Units
2025-02-14+26,650→ 26,650 total→ Common Stock (26,650 underlying) - Award
Stock Options (Right to Buy)
2025-02-14+40,000→ 40,000 totalExercise: $56.69Exp: 2035-02-13→ Common Stock (40,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date.
- [F3]The options vest and become exercisable, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date, as to 6.25% of the total number of shares of common stock subject to the options upon the Reporting Person's completion of each successive three months of service to the Issuer after February 14, 2025, such that the option shall be fully vested and exercisable on February 14, 2029.
Issuer
RHYTHM PHARMACEUTICALS, INC.
CIK 0001649904
Entity typeother
Related Parties
1- filerCIK 0002027261
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 9:44 PM ET
- Size
- 14.5 KB